By David Douglas
Reuters Health News
Nutritional support during antiviral treatment for hepatitis C helps limit weight loss and improves quality of life, Dutch researchers say.
"In our opinion, such nutritional support should be considered in all patients during antiviral treatment with pegylated-interferon alfa and ribavirin," Dr. Karel J. van Erpecum told Reuters Health by email.
Dr. van Erpecum of University Medical Center Utrecht and colleagues enrolled 53 patients in a randomized trial, assigning 27 to receive advice on nutrition, including a recommendation for frequent small meals, plus an energy- and protein-rich flavored drink to be taken daily before bedtime. The remaining patients received the advice and the supplements only if their weight dropped by at least 5% from baseline, according to a report online June 30th in the Journal of Hepatology.
At 24 weeks, both groups had lost weight, but the average loss was only 0.3 kg (0.3%) in the nutritional support group, vs 5.4 kg (6.9%) in the control group.
Similarly, Jamar Hand Grip Strength fell in both groups, but the decrease was minimal in the support group (from 40.7 to 39.7 kg), whereas it was significant in the control group (from 40.3 to 32.0 kg).
Digestive symptoms increased and quality of life scores deteriorated in both groups, but the impairments were significantly less in the intervention group. There was also a considerable reduction in energy, proteins and fat intake in the control group, while intake increased in the support group.
There was no significant difference in sustained virologic response between groups based on intention-to-treat analysis but there were significantly fewer patient-reported side effects in the preventive group.
Overall, the researchers conclude, "Preventive nutritional advice plus supplementation prevents weight loss and catabolic state during antiviral therapy for HCV, with improved digestive symptoms and quality of life."
What's not clear, Dr. van Erpecum added, are the potential benefits of nutritional supplementation during "triple therapy," which is currently advised for hepatitis C virus genotype 1 and includes the protease inhibitors boceprevir or telaprevir along with PEG-interferon and ribavirin. "These protease inhibitors are ingested together with meals, which could in theory decrease weight loss and catabolic state," he said.
J Hepatol 2012.
By David Douglas
(Reuters) - Vertex Pharmaceuticals Inc (VRTX.O) reported further declines in sales of its hepatitis C drug Incivek and lowered its full year forecast for the medicine, but promising data on another drug for the virus lifted its shares more than 5 percent.
Vertex reported on Monday positive results from a very small, early stage trial of a hepatitis C medicine licensed from Alios BioPharma called ALS-2200 that appeared to allow investors to ignore falling Incivek sales. The experimental drug belongs to a class of medicines called nucleotide analogues, or nucs.
"It's all due to the data on their nuc," Brean Murray, Carret & Co analyst Brian Skorney said of the Vertex share jump.
He said the data looked comparable to early data from closely watched drugs being developed by Gilead Sciences Inc (GILD.O) and by Bristol-Myers Squibb Co (BMY.N).
"It puts them back in the hep C race," Skorney said. "It makes them a real player again."
If all goes well, Vertex said it could potentially begin pivotal Phase III testing of combinations including ALS-2200 by the end of 2013.
ISI Group analyst Mark Schoenebaum said the early ALS-2200 data surpassed expectations and agreed that it could be a serious potential rival for the drugs that Gilead and Bristol-Myers paid billions of dollars to acquire by buying other companies.
He added that Wall Street had not yet factored in the drug's potential in assessing the future value of Vertex.
"The Street has very little in the Vertex model for next generation hep C assets, so we think of this drug as all upside at this point," Schoenebaum said.
Second-quarter Incivek sales of $328 million fell short of Wall Street estimates of about $360 million and first-quarter sales of $356.9 million.
The company said it now expects full-year Incivek sales of $1.1 billion to $1.25 billion, down from its prior forecast of $1.5 billion to $1.7 billion.
Incivek, which was approved in May 2011, earlier this year eclipsed $1 billion in total sales, making it the fastest prescription drug to reach that mark in pharmaceutical history. But it must be taken with the difficult to tolerate injectable drug interferon and Incivek's life as a blockbuster is likely to end once all-oral treatment options become available over the next two years.
The continued decline in sales could indicate that patients are already beginning to wait for interferon-free regimens with fewer side effects being developed by several companies, including Vertex.
The company said it was still getting 70-75 percent of new hepatitis C prescriptions, but the number of patients beginning treatment has declined from initial demand. In addition to some patients delaying treatment, Vertex said many potential new patients were being recruited into clinical trials of new medicines being pursued by many companies.
"We believe ALS-2200 could become an important part of all-oral treatment regimens," Chief Executive Jeffrey Leiden told analysts on a conference call.
He said the company would move quickly to advance ALS-2200 into Phase II testing, and to develop all-oral regimens that include ALS-2200 in combination with its own medicines or those being developed by rival drugmakers.
Sales of the new cystic fibrosis drug Kalydeco were $46 million for the quarter, topping Wall Street estimates of about $41 million. Kalydeco, the first drug to treat the underlying cause of the life-shortening lung disease rather than just symptoms, won U.S. approval in late January and European approval just last week.
Kalydeco treats about 4 percent of cystic fibrosis patients with a specific gene mutation. It is currently testing Kalydeco in combination with another experimental drug with the hope of eventually addressing the larger cystic fibrosis population.
Vertex posted a net loss of $65 million, or 31 cents per share, after taking a $78 million charge as reserve against potential for excess Incivek inventory. That compared with a loss of $174 million, or 85 cents per share, a year ago.
Total revenue for the quarter of $418.3 million included $28 million in royalty payments from Johnson & Johnson (JNJ.N), which holds overseas rights to Incivek. That was short of analysts' revenue estimates of $471.2 million.
Vertex shares, which were already up about 50 percent this year, rose 5.3 percent to $52.60 in extended trading from their Nasdaq close at $49.96.
(Reporting by Bill Berkrot in New York; Editing by Bernard Orr, Leslie Gevirtz and Tim Dobbyn)
ALS-2200-Vertex Announces Positive Results from Viral Kinetic Study in People with Hepatitis C
Vertex Announces Positive Results from Viral Kinetic Study of the Nucleotide Analogue ALS-2200 in People with Hepatitis C
- 4.54 log10 median reduction in HCV RNA observed in people with genotype 1 hepatitis C treated with a once-daily 200 mg dose of ALS-2200 for seven days; treatment was well-tolerated-
Vertex surges as rival hep C contender plays catch-up in clinic
Vertex investors barely noted yesterday evening that revenue from Incivek slipped in the second quarter. Their attention was on ALS-2200, a hepatitis C nucleotide analogue that has elbowed its way into the frenzied race for a near-term approval for an all-oral therapeutic regimen
"It puts them back in the hep C race," Skorney told the news service about the data. "It makes them a real player again."
"There was a median 4.54 log reduction in hepatitis C virus RNA in people with genotype 1 chronic hepatitis C who were new to treatment after seven days of dosing with 200 mg of ALS-2200 once daily," Vertex reported. Next Vertex says it will study ALS-2200 in a combo trial with Incivek. And if everything continues as hoped Vertex says it can launch a pivotal Phase III next year.
Late last week Gilead laid out an ambitious schedule for its combination hep C program, promising to race into a late-stage study later this year after gaining proof-of-concept human data for its NS5a inhibitor. The biotech mapped out a two-year clinical game plan that matches GS-5885 with 7977.
A Debate on Liver Fibrosis Progression in HIV/HCV-Coinfected Patients
The rate of fibrosis progression is high early in the course of HCV infection, but whether it later declines is unclear.
In late 2011, Vogel and colleagues published a study showing that HIV-infected men with primary hepatitis C virus (HCV) infection had a higher rate of liver fibrosis progression than would be expected in early HCV infection — but that it declined upon resolution of primary HCV infection.1 Now, Fierer and colleagues have written a letter to the editor, questioning the use of transient elastography to measure fibrosis progression in that study.2
Fierer and colleagues argue that although transient elastography provides an accurate assessment of liver stiffness — and thus fibrosis — in the setting of chronic HCV infection, it might not do so during primary HCV infection, when acute inflammation is present. Inflammation can falsely elevate the liver-stiffness score, making the fibrosis stage appear to drop sharply as the acute inflammation associated with primary HCV infection subsides.
Fierer and colleagues assert that liver biopsy provides a more accurate assessment of fibrosis in the setting of primary HCV infection. In support of this assertion, they report the results of 29 liver biopsies (11 reported previously3) performed in HIV-infected men with primary HCV infection. They noted high histopathologic stages of fibrosis early in the course of primary HCV infection, which persisted through the first 1 to 2 years of infection. Contrary to what was reported by Vogel and colleagues, fibrosis stage correlated with increasing time from initial HCV infection.
Notably, both the Vogel and Fierer cohorts were very small with relatively short follow-up, which means that we still lack definitive data beyond the first 1 to 2 years of primary HCV infection. Nevertheless, these studies are important because they demonstrate that HIV-infected men who acquire HCV infection tend to have an elevated rate of fibrosis progression during the early stages of HCV infection. According to recently published data, this elevated rate is associated with increased risks for end-stage liver disease, hepatocellular carcinoma, and all-cause mortality.4 Whether early treatment of HCV infection with new antivirals will alter the course of incident HCV infection in HIV-coinfected individuals remains to be seen.
— Sonia Nagy Chimienti, MD
Published in Journal Watch HIV/AIDS Clinical Care July 30, 2012
- Medline abstract (Free)
- Posted by New HCV Drugs
- File Under Milk thistle
Really? The Claim: Milk Thistle Combats Liver Disease
By ANAHAD O'CONNOR
In the world of alternative medicine, milk thistle is the treatment of choice for liver disease, particularly chronic infection with hepatitis C.
But now more evidence has come in: In a careful, double-blinded study financed by the National Institutes of Health, researchers at the University of North Carolina found that milk thistle had no real effect on people with chronic hepatitis C.
The study, one of the most rigorous to date on this topic, followed 154 people with the disease for 24 weeks. Some were given a placebo while others received silymarin, the active ingredient in milk thistle, three times a day in either normal or high doses.....
Silymarin Is Ineffective for Chronic Hepatitis C Virus Infection
Published in Journal Watch Gastroenterology July 27, 2012
In the most rigorous trial to date, oral silymarin was not superior to placebo in decreasing disease activity.
Silymarin is a botanical extract of milk thistle commonly used by patients with liver disease. In vitro studies have demonstrated antiviral, anti-inflammatory properties of silymarin in hepatitis C virus (HCV) replicon systems. However, the few efficacy studies conducted in patients with chronic HCV infection have produced mixed results.
In a new multicenter, double-blind, placebo-controlled efficacy trial, investigators randomized 154 patients (median age, 54; 71% men) with chronic HCV infection who previously failed interferon-based therapy to receive 420 mg of silymarin, 700 mg of silymarin, or placebo three times daily for 24 weeks. The two oral doses of pure silymarin were determined by earlier dose finding studies and were three to five times higher than concentrations used in previous studies. The primary endpoint was a serum alanine aminotransferase (ALT) level of 45 U/L or a 50% reduction from baseline ALT to a level <65 U/L. Secondary endpoints included HCV RNA levels and quality-of-life indicators.
After 24 weeks of treatment, only two patients in each group achieved the primary endpoint. The mean decline in ALT levels at the end of treatment, the mean change in HCV RNA levels, and the quality-of-life indicators did not differ among the three groups.
Comment: This trial definitively demonstrates that silymarin, even at three to five times the typical dose, is ineffective in treating patients with chronic HCV infection. Unlike previous trials, this study used a pure, quantifiable formulation of silymarin and well-defined outcomes, its cohort was large and representative of the patient population, the treatment period was sufficiently long, and both medication and visit adherence rates were high. Clinicians should quote this study when addressing patients' questions regarding the use of milk thistle for treating HCV infection.
— Atif Zaman, MD, MPH
- Medline abstract (Free)
U.S. issues warrant for Canadian linked to illegal Internet pharmaceutical scheme
By Stephen Maher, Postmedia News July 30, 2012
An American judge issued an arrest warrant Monday for a Canadian businessman over his role in an illegal Internet pharmacy operation.
Judge Irma Gonzalez, in the U.S. District Court for the Southern District of California, in San Diego, issued the warrant after Nathan Jacobson failed to show up for a sentencing hearing.
Jacobson, who grew up in Winnipeg and frequently hobnobs with senior Canadian politicians, was to be sentenced for conspiring to commit money-laundering.
Jacobson has offices and homes in Toronto and Israel. He pleaded guilty in May 7, 2008, to conspiracy to commit money laundering, according to U.S. attorney Phil Halpern in San Diego, but the plea has been sealed since then.
Jacobson and 17 others were charged in 2006 by a grand jury with 313 counts related to Affpower, an Internet pharmacy that dispensed drugs to Americans without legal prescriptions. Many of his co-accused have since been convicted, receiving long prison sentences.
Jacobson's role was clearing the payments — more than $46 million — through RX Payments Ltd., a credit-card clearing company registered in Malta but operating in Tel Aviv, Israel, according to court documents.
As part of his plea agreement, Jacobson agreed to forfeit $4.5 million.
Prosecutors hope that the judge will sentence him to prison time.
Continue Reading @ Montreal Gazette
Hospitals and blood banks are adopting new measures to improve the safety of donated platelets—the tiny cells that make blood clot and heal injuries but that also present the No. 1 infection risk in the U.S. blood supply, the Wall Street Journal reported.
The biggest risk in the nation's blood supply is no longer HIV or hepatitis C, it's bacterial contamination of platelets, resulting in at least 20 deaths and hundreds of adverse reactions in recent years, health experts say.
A growing number of studies show that standard tests performed by blood banks before they ship platelets to hospitals miss the majority of contaminated platelets. Unlike other blood components such as red cells, which are refrigerated, platelets must be stored at room temperature to remain effective, but during storage periods that last up to five days bacteria can grow and multiply.
About 150 hospitals have adopted a new contamination test, made by Verax Biomedical Inc., that can be administered immediately before patients get a transfusion. Initially approved by the Food and Drug Administration in 2007, one barrier is cost: It adds about $25 to $30 to the average $540 cost of a unit of platelets.
- Posted by New HCV Drugs
- File Under HCV News
Two new targets have been discovered for antiviral therapies and vaccines strategies that could enhance the body's defenses against such infectious diseases as West Nile and hepatitis C. The targets are within the infection warning system inside living cells.
No vaccines exist for the viruses that cause West Nile or hepatitis C. New therapies are urgently needed to prevent and treat serious infections by these and related viruses. The University of Washington is engaged in a major, multipronged effort to design therapeutics that harness the warning signals the body produces when viruses attack. Such therapies would prod people's cells into launching a stronger counterattack to control infections by elusive viruses.
UW specialists in how the body fends off viral diseases are studying pattern recognition molecules, called RIG-I-like receptors, found inside living cells. When these receptors detect virus invasions, they call in the immune system to fight infection. Scientists in the laboratory of Dr. Michael Gale, Jr., UW professor of immunology, observed an interaction between these molecular dispatchers and a protein called 14-3-3 epsilon This protein acts a docking station where other proteins can gather. There they can more efficiently send out signals in response to threats.
The researchers noticed that the interaction between the alert trigger (RIG-I) and the docking station (14-3-3 epsilon) steps up when cells were infected with virus. The agitation prompts RIG-I to work with other proteins, such as TRIM25.
Those proteins are essential for RIG-I to warn the immune system to respond to a virus intruder. "Our work also demonstrated that RIG-I binding to 14-3-3 epsilon is important for RIG-I to move from within the cell where it detects viral RNA to a location on the cell's membrane where the cell's antiviral defenses can be activated," said Dr. Helene Liu, a postdoctoral fellow who led the study. The move is somewhat like running from the inner corridors of a building to a window to call for help.
"By understanding the molecular partners and location changes that RIG-I requires to convey its signal that virus is present in a cell, we can start to design therapeutics that can trigger this process to kick-off an antiviral immune response and fight virus infection," Liu said. The scientists reported these initial findings in the May 17 issue of Cell Host & Microbe.
The Gale laboratory reports additional observations on the RIG-I-like receptors in the August issue of Immunity, published online July 26. Postdoctoral fellows Dr. Mehul Suthar and Dr. Hilario Ramos found that, during West Nile virus infection, an RIG-I like receptor called LGP2 promotes the survival and activity of CD8+ T white blood cells, commonly called killer T cells.
These disease-fighters eliminate virus-infected cells from the body. "By increasing the ability and length of time CD8+T cells can work within the body when West Nile virus is present, the immune system is strengthened and has a better chance of eliminating the virus," Suthar commented. Ramos added, "Based on this work, we can consider new ways to boost vaccine effectiveness through design of adjuvants or immune-stimulants. These might be applied within a vaccine approach to regulate LGP2 to enhance immunity to infection." Gale directed the research effort for both projects. He heads the Center for Study of Innate Immunity to Hepatitis C Virus and the Center for Immune Mechanisms of Flavivirus Control, as well as two National Institutes of Health-funded multi-million dollar programs to develop new antiviral therapies and vaccine adjuvants.
"These two new discoveries," Gale said, "greatly advance our knowledge of how the body senses and responds to virus infection and provide us with new avenues to explore when designing antiviral therapies and new vaccines. "West Nile virus is an emerging virus that has spread across the United States, and hepatitis C virus infects over 170 million people globally.
Both viruses are devastating to the health of the individuals they infect. That is why the development of new clinical resources such as vaccines and antivirals for each is so critical." West Nile virus is spreading throughout North America through infected mosquitoes. It can cause paralysis and death in people. Hepatitis C virus is transmitted through contact with blood or blood products containing the virus. It causes swelling and inflammation of the liver.
Most hepatitis C infections are persistent because the virus evades the immune defenses that normally limit the course of disease. The virus generates a chronic liver inflammation which scars the organ's tissues. The scarring can lead to liver failure and increases the risk of liver cancer. While therapies are available to treat hepatitis C infections, these treatments have harsh side-effects and are not effective in all people. No antiviral therapies are available to treat people infected with West Nile virus.
Read more at: http://medicalxpress.com/news/2012-07-infection-cells-antiviral-vaccine-strategies.html#jCp
- Monday, July 30, 2012
- Posted by New HCV Drugs
- File Under HCV Worldwide Asia Australia Egypt
July 30, 2012
Progress has been made in the prevention of the spread of hepatitis C virus in health care situations in Egypt, but a comprehensive plan to prevent and control the disease is needed, according to results in the Morbidity and Mortality Weekly Report.
Egypt has a 10% prevalence of chronic hepatitis C among those aged 15 to 59 years, making it the largest burden of the virus worldwide, according to the report. Inadequate infection control during medical and dental procedures is the primary reason for this burden. In 2001, the Egyptian Ministry of Health and Population (MOHP) created a program to reduce this burden. A care and treatment program was launched in 2008.
Among patients receiving dialysis, the annual incidence of hepatitis C reduced from 28% to 6%, mostly in part to infection control programs implemented at MOHP facilities. In addition, there have been 23 hepatitis treatment facilities established in the country, which have provided care to almost 190,000 people with the disease.
During 2001, there were nearly 280 million injections given in Egypt, and an estimated 8% of these may have been unsafe. When the MOHP facilities were assessed, the following were found: there were few health care workers with knowledge of infection control; there were few infection control programs in the facilities; there was little understanding about standard precaution among health care workers; and there were inadequate procedures for equipment reprocessing, sterilization and waste management. Infectious control guidelines were developed in 2003, and after the implementation, improvements were observed.
The MOHP created the National Committee for the Control of Viral Hepatitis in 2006, which developed a National Control Strategy for Viral Hepatitis. This strategy called for effective surveillance, prevention measures to reduce the spread of both hepatitis B and hepatitis C and expansion of access to care and treatment. The program has cost the Egyptian government $80
CDC. MMWR. 2012;61:545-549.
The researchers report no relevant financial disclosures.
- Posted by New HCV Drugs
Sorafenib improved survival regardless of baseline characteristics in HCC patients
Bruix J. J Hepatol. 2012;doi:10.1016/j.jhep.2012.06.014.
Patients with hepatocellular carcinomas had higher survival and disease control rates when treated with sorafenib compared with placebo, regardless of pretreatment disease characteristics, in a recent study.
Researchers performed subgroup analyses on 602 participants in the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol trial. These patients randomly received 400 mg sorafenib (n=299) or placebo (n=303) twice daily, and analysis was conducted to determine whether patients’ baseline characteristics influenced drug efficacy and safety or survival rates.
Patients were split into subgroups based on disease etiology, tumor burden and stage, performance status and previous treatment, and then further divided into subsets. Survival rates were greater among treated patients compared with placebo patients, with HRs ranging from 0.50 to 0.85 (95% CI for all) across all subsets, compared with an HR of 0.69 (95% CI, 0.55-0.87) for the entire cohort. Median time to progression also was likely to be higher among treated patients (HR range 0.40-0.64 across all subsets), excluding those who tested positive for HBsAg antigen (HR=1.03) (95% CI for all). Among all subgroups, sorafenib improved disease control rates, including treated patients (34.4%-54.4%) compared with placebo patients (26.0%-43.1%).
The incidence rate of adverse events, which did not differ significantly, included diarrhea, hand-foot skin reaction and fatigue. Treatment-related events occurred in 71.9% to 84.9% in subgroups of sorafenib patients and 43.2% to 60.7% of those receiving placebo. Serious events occurred in 9.4% to 14.6% of treated patients and 5% to 25% of placebo patients.
“The efficacy and safety of sorafenib, relative to placebo, in patients with advanced HCC and well-preserved liver function do not appear to be affected by baseline health status, disease etiology, tumor burden, tumor stage or prior therapy,” the researchers concluded.
- Posted by New HCV Drugs
- File Under liver cancer
- Brian I. Carr, MD, FRCP, PhD (Guest Editor)
- IRCCS S. de Bellis National Institute for Digestive Diseases, Castellana Grotte (BA), Italy; Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA
- PDF (77 KB)
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide, with 80% being in the developing world, in which the incidence is starting to decline, in part due to hepatitis B virus (HBV) vaccination. By contrast, HCC is increasing in the developed world, with hepatitis C virus (HCV) and obesity being contributing factors. Only a minority of patients present with tumors small enough to be amenable to potentially curative resection and the remaining patients have a typical survival of less than 12 months. Incidence-to-death ratios are thus almost 1. Although liver transplantation is potentially curative for two diseases simultaneously—namely, for HCC and for the underlying cirrhosis—it is not curative for most patients with advanced HCC and is not available to many patients with limited-stage disease due to poor availability of donor organs or, in the less developed world, due to its high cost. The reasons for the disappointing survival in patients with large HCCs are not entirely clear, unless they have concomitant portal vein invasion, which provides a route to vascular dissemination of the tumor. There are huge geographical variations in incidence and, for patients with cirrhosis, a male to female predominance. The reasons for the large gender disparity are far from clear. Geography may relate to the incidence of predisposing hepatitis and also to dietary contamination with mycotoxic and other hepatocarcinogens. Many of the predisposing causes are known, unlike with most other cancers, and include cirrhosis from any cause, hepatitis B and C chronic carrier status, aflatoxin B1 contamination of stored rice and grains in non-refrigerated conditions, and chronic alcoholism. These factors provide the potential for prevention strategies, including hepatitis virus vaccination or treatment, refrigeration of rural stored food grains, and psychological interventions for chronic alcohol abuse. The large number of years needed for a patient with a predisposing risk such as chronic hepatitis B or C or alcoholism to develop HCC makes it feasible to implement screening for early detection of those known to be at risk, similar to Pap smears for cancer of the cervix uteri.
All of the aforementioned data have been known for decades, with ultrasound screening,
percutaneous ethanol injection (PEI), surgical resection, liver transplant, or chemoembolization being the mainstay of the clinical practice. Why then the need for a special edition of Seminars in Oncology that is devoted to HCC? As summarized in the first article by this guest editor, the last 5 years have seen a great number of advances in a wide array of investigative areas, some of which did not even exist 10 years ago, including proteomics and genomic analyses of clinical samples in treatment decision-making, availability of targeted, non-cytotoxic (chemotherapy) kinase inhibitor therapies (sorafenib, regorafenib, brivanib, linifanib, erlotinib, bevacizumab, and temsirolimus, to name only a few) against specific steps in the cellular proliferation pathways, a vast array of potential new therapies directed against various aspects of cellular protein turnover and against metabolic pathways, newer internal radiation agents (yttrium 90, holmium 66, rhenium 88) and external radiation imaging techniques (IMRT) and particle types (protons), increasing availability of peripheral blood circulating tumor cells as substrates for genomics analysis, a whole array of potential new tumor markers, several of which are becoming part of clinical practice (L3 (fucosylated) form of alpha fetoprotein [AFP-L3], des-gamma-carboxyprothrombin [DCP], glypican-3) and newer diagnostic imaging modalities (contrast-enhanced ultrasound, flow magnetic resonance imaging).
The introduction of sorafenib into routine clinical practice has obliged us to re-evaluate some previously held views, due to some of the associated clinical trial findings. In particular, there are two. First, that survival was enhanced in treated patients compared to control patients, without meaningful tumor shrinkage. Thus decades of oncology thinking that tumor shrinkage was a key to a treatment's usefulness (and our discussions with our patients) needs to be re-appraised. Second, this agent, and many in its class, has the tumor vasculature as a prime target. Given that tumor size can remain unchanged and can be associated with enhanced survival, tumor stability (measured in part as time to tumor progression) becomes increasingly useful as a goal in its own right. We have spent decades in the clinic measuring tumor size and using this as a hallmark for the effectiveness of our therapy.
We now need to develop for clinical use semiquantitative techniques for measuring tumor blood flow and vascularity, and this is in process. Three other new general ideas have recently found support in recent experimental work. They are that patient subsets with likely different prognoses can be identified by molecular probing of tumor biopsy samples and that gene expression patterns of the underlying non-tumor liver may be important in predicting, and likely influencing, HCC growth. A consequence of these two ideas is the importance for clinical decision-making of tumor (and perhaps non-tumor) biopsy. We have entered a very exciting era in HCC clinical and basic research, with profound changes resulting in HCC clinical practice. This series of articles gives us a glimpse of the cornucopia that is unfolding in both diagnostics and therapy. The field of HCC studies promises to be different again in another 5 years, based upon what is unfolding now, especially as a consensus emerges as to which gene signature patterns are reliable and useful, together with the results of the many clinical trials that are just beginning or are being planned, using combinations of therapies that target differing pathways, or combinations of these agents with either chemotherapy or regional radiotherapy.
Four Michigan Facilities Linked to New Hampshire Hepatitis C Investigation
Contact: Angela Minicuci (517) 241-2112
FOR IMMEDIATE RELEASE: July 30, 2012
LANSING - The Michigan Department of Community Health (MDCH) has been investigating the employment history of a hepatitis C-positive healthcare worker who was arrested recently in New Hampshire for allegedly obtaining injectable narcotics and infecting patients with the hepatitis C virus.
Hepatitis C is a bloodborne viral infection, estimated to infect 1.6 percent of the U.S. population. It can cause inflammation of the liver that may lead to chronic health issues. Most infected individuals do not know they have the virus because hepatitis C can damage the liver for many years with few noticeable symptoms.
MDCH has confirmed that this individual previously worked in at least six Michigan facilities from 2003-2007 and is known to have been infected with hepatitis C since at least June 2010. The investigation has not uncovered evidence that the individual was infected with hepatitis C while employed at any Michigan facility. A negative hepatitis C test result at one hospital during his employment allows MDCH to exclude two hospitals from further examination as there was no risk posed by this individual to patients at these facilities.
MDCH recommends that all individuals with known risk factors for hepatitis C virus be tested. If you were a patient at one or more of the facilities listed below during the identified time periods and you received an injectable narcotic, you may have a risk factor of which you were previously unaware. You should consult the facility contact identified below and/or your primary care provider regarding hepatitis C testing. While the receipt of an injectable narcotic at these facilities during these time frames may represent a possible increased risk for hepatitis C for patients, it is clearly not the only risk. If you do not know if an injectable narcotic was administered to you, contact the facility to find out more information. While this testing is important, it need not be considered an emergency procedure.
"Hepatitis C is a chronic condition that can damage the liver for many years without noticeable symptoms," said Dean Sienko, Interim Chief Medical Executive of the MDCH. "Our goal of recommending testing is to ensure the appropriate use of the modern medicine now available to prevent deaths from hepatitis. In order to help potentially affected individuals, we are asking patients to get tested to protect their health."
Due to the length of time since potential exposure as well as the prevalence of the disease in the general population, a positive test result for patients of the facilities named below may not conclusively prove that hepatitis C was acquired from the individual currently under investigation at these facilities.
The Centers for Disease Control and Prevention (CDC) estimates that more than 2 million U.S. citizens born from 1945 through 1965 have been infected with the virus and is currently recommending testing for everyone born in that time frame. Hepatitis C can be detected with blood tests and treated with antiviral medications.
Identified Michigan hospitals, dates of interest, and facility contact information:
Dates of Interest
Facility Contact Information
|Sinai Grace Hospital*||June-October 2005||1-888-300-3627 or www.dmc.org/mdch|
|Harper Hospital**||October 2005-September 2006||1-888-300-3627 or www.dmc.org/mdch|
|University of Michigan Hospital (Main Campus)||September 11-December 8, 2006||1-877-233-4040|
|Oakwood Annapolis Hospital||January 15-September 15, 2007||1-734-467-4111|
*Patients who underwent procedures in interventional radiology that required intravenous narcotics *Patients who underwent procedures in the cardiac catheterization laboratory
Because this is an ongoing investigation, MDCH will continue to identify past employment history and work with all identified facilities in Michigan as well as the CDC. The MDCH will provide any updates to this information as it becomes available. For questions and information about hepatitis C, please visit the MDCH website at www.michigan.gov/hivstd or the CDC website at www.cdc.gov/hepatitis.
# # #
Related-UMHS one of six Michigan facilities linked to New Hampshire hepatitis C investigation
An internal review requested by MDCH shows that the individual worked at the U-M Health System for three months of 2006; from Sept. 11 to Dec. 8. He was an interventional radiologic technologist, a position in the Department of Radiology’s interventional radiology procedures unit team for vascular interventional procedures. He did not have responsibility for administering medication to patients.
The investigation has not uncovered evidence that the individual was, in fact, infected with Hepatitis C while employed at UMHS or any other Michigan facility. There was no increase in the number of cases of Hepatitis C reported in the last quarter of 2006 after he worked at UMHS, as well as no increase in the number of cases for subsequent years.
As a precaution, patients who received injectable narcotics at the U-M Health System’s main medical campus in Ann Arbor from Sept. 11 – Dec. 8, 2006, may contact 877-233-4040, toll free. The call center for patient inquiries will open July 31 at 8 a.m. Patients who call will receive personalized help to determine whether they need testing for Hepatitis C. If testing is recommended, it will be offered free of charge.
Due to the length of time since potential exposure, a positive Hepatitis C test result for patients who were treated during this employee’s tenure at UMHS will not conclusively prove that hepatitis C was acquired at UMHS.
The individual under investigation worked in at least five other Michigan health care facilities from 2003-2007 and has been infected with Hepatitis C since at least June 2010. Read the Michigan Department of Community Health press release for a complete list of Michigan health institutions for which this individual worked. A negative test result at one hospital during his employment allows MDCH to exclude two hospitals from further examination as there no risk posed by this individual to patients at these facilities.
Hepatitis C is a blood-borne viral infection, estimated to infect 1.6 percent of the U.S. population. Most infected individuals do not know they have the virus because Hepatitis C can damage the liver for many years with few noticeable symptoms. The Centers for Disease Control and Prevention (CDC) estimates that more than 2 million U.S. citizens born from 1945 through 1965 – the baby boomers – have been infected with the virus and is currently recommending testing for all of those born in that time frame. Hepatitis C can be detected with blood tests and can be treated with antiviral medications. The goal of testing is to leverage the appropriate use of effective treatments that are now available to prevent deaths from hepatitis.
MDCH will continue to work with hospitals in Michigan as well as the CDC. For questions and information about Hepatitis C, please visit the MDCH website at www.michigan.gov/hivstd or the CDC website at www.cdc.gov/hepatitis.
All media inquiries should be directed to MDCH at 517-373-3740.
For more information view the MDCH press release.
Related- Four Michigan Facilities Linked to New Hampshire Hepatitis C Investigation
NEW YORK (Reuters Health) Jul 27 - More than 50% of patients with chronic hepatitis C suffer from fatigue, which in many cases would improve with antiviral therapy, a new paper says.
The authors say their data "indicate that therapy of HCV can result in significant and sustained improvement in clinical symptoms, and that the measurement of fatigue using visual analog scales is successful in capturing these changes."
"Thus, patients with relatively nonsignificant biochemical or histologic disease, but who have troublesome symptoms such as fatigue, should be considered for antiviral therapy," Dr. Jay H. Hoofnagle from National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland and colleagues wrote online June 30th in the Journal of Hepatology.
On the other hand, they caution, "Improvements in fatigue scores were seen predominantly among patients who had moderate or severe levels of fatigue before treatment, and there was little or no improvement in patients who reported minimal fatigue initially. Such findings suggest that there is little room for improvement in fatigue among those with lower levels at baseline, or that the visual analog scale is not sensitive enough to detect minor improvements."
Their conclusions are drawn from the multicenter Virahep-C study, in which 401 patients with chronic hepatitis C, genotype 1 received peginterferon alfa-2a and ribavirin with extensive monitoring of HCV viral kinetics, immune function, genetics and interferon signaling pathways.
Treatment continued for up to 48 weeks. Just over half of the patients (207/401, 52%) reported fatigue at the time of screening. The prevalence and severity of fatigue were higher for women than for men, and fatigue was more common in patients with cirrhosis (66%) than in those with minimal (49%) or moderate fibrosis (53%).
In multivariate analysis at screening, younger age and lower alanine aminotransferase level were the only factors independently associated with more severe fatigue.
During treatment, the prevalence of fatigue increased from 52% to 78% at week four and ranged from 67% to 79% for the duration of treatment.
By 12 weeks after the end of therapy, the prevalence of fatigue had declined to 36% in responders and 42% in nonresponders, and the median fatigue visual analog scores had declined from 25 mm at baseline to 11 mm in responders and 17 mm in nonresponders.
Fatigue improved to a significantly greater extent among patients who achieved a sustained virologic response than among patients who never became HCV RNA negative (nonresponders).
However, the presence or severity of fatigue did not change significantly among patients who had virologic relapse or breakthrough.
Fatigue scores were associated with depression, but controlling for the presence of depression did not alter the significance of the improvements in fatigue severity after successful completion of therapy.
Dr. Hoofnagle did not respond to a request for comments.
J Hepatol 2012.
- Posted by New HCV Drugs
- File Under liver cancer
- Liver cells normally produce glucose to help maintain healthy blood-sugar levels, but they lose that ability when they become cancerous, this study shows.
- This change might benefit tumor cells by helping them grow and proliferate.
- The study tracks how this loss happens and suggests that reversing it might offer a new way to treat this often-deadly disease.
- Levels of enzymes in the gluconeogenesis pathway were drastically reduced, along with transcription factors involved in the expression of the genes encoding those enzymes.
- miR-23a expression was significantly up-regulated in the animal model and in primary human HCC.
- miR-23a suppresses the enzyme glucose-6-phosphatase and the transcription factor PGC-1a, two important components of the gluconeogenesis pathway.
- Interleukin-6 and Stat-3 signaling cause the upregulation of miR-23a.
- Posted by New HCV Drugs
- File Under cirrhosis
New genetic target found for diuretic therapy
CINCINNATI—Researchers at the University of Cincinnati (UC) have identified a new genetic target for diuretic therapy in patients with fluid overload—like those with congestive heart failure, liver cirrhosis or kidney failure.
These results, being presented in the July 30 advance online edition of the journal Proceedings of the National Academy of Sciences (PNAS), may lead to the first new diuretic therapy in 25 years and could help patients who experience diuretic resistance.
Manoocher Soleimani, MD, professor and chief in the division of nephrology and hypertension, says the role of diuretics is to increase urine output and help patients rid themselves of excess fluid when their kidneys are unable to do so.
"For the last several decades, physicians have been using diuretics either alone or in combination to help patients experiencing water retention," he says, adding that this can occur in patients with heart failure, kidney failure or other serious illnesses. "The most common diuretic used worldwide is hydrochlorothiazide, which works by inhibiting the kidneys' ability to retain water; these drugs can also be used to lower blood pressure. The reason they are so widely used is because they are mild and don't cause severe loss of fluid.
"However, they aren't effective with every patient."
In this study, researchers examined the specific segments of the kidneys, called tubules, and the salt-absorbing genes working there.
"The NaCl, or sodium-chloride, co-transporter (NCC), is targeted by hydrochlorothiazide and drugs in that class; it is located in the close proximity of the chloride-absorbing transporter pendrin, both of which absorb salt in the kidney," Soleimani says. "When pendrin is deleted from the body, there is no effect on salt excretion. We thought that pendrin was present to help NCC function in some way, and by using knockout animal models in this study, we found that these two genes cross-compensate for one another, and if NCC is not working, pendrin kicks in to do its job."
He says genetically engineered animal models without NCC had regular urine output and salt excretion; the same results occurred in models without pendrin. However, models lacking both genes lost large amounts of salt, were 40 percent smaller in size and produced an excessive volume of urine.
"In addition to experiencing major volume depletion, mice lacking both genes developed kidney failure," Soleimani says. "We were able to show that all of these problems resulted from salt wasting; when we put these models back on high-salt diets, the problems including electrolyte abnormalities and volume depletion were all corrected after just one week."
Soleimani says these findings could lead to a targeted diuretic therapy that inhibits pendrin, further helping patients with severe fluid overload who may not respond well to hydrochlorothiazide.
"By giving a pendrin inhibitor in conjunction with thiazide, a mild diuretic, it could greatly relieve fluid retention, providing another treatment option and improving patient outcomes," he says.
Jul 30, 2012 06:05AM
Bristol CEO says Gilead holding out on hep C tie-up
Lack of Gilead and BMS teamwork on hep C draws ire
Gilead wows analysts as 7977 combos quell hep C in most patients
Analysts pounce on positive Phase II data on hep C combo
Source - http://www.powercapitalconsulting.com/Biotechnology.php
Vertex Announces Positive Results from Viral Kinetic Study of the Nucleotide Analogue ALS-2200 in People with Hepatitis C
- 4.54 log10 median reduction in HCV RNA observed in people with genotype 1 hepatitis C treated with a once-daily 200 mg dose of ALS-2200 for seven days; treatment was well-tolerated-
Median Change From
Baseline After 3 Days
Median Change From
Baseline After 7 Days
|15 mg |
|50 mg |
|100 mg |
|200 mg |
*One patient had an HCV RNA level below the limit of detection (Roche COBAS Taqman HCV test, Version 2) during the study.
**Four patients had HCV RNA levels below the limit of quantification (<LOQ = < 25 IU/mL) during the study.
Zach Barber, 617-444-6992
Erin Emlock, 617-444-6992
Dawn Kalmar, 617-444-6992
Michael Partridge, 617-444-6108
Stay Updated: Get Updates For HCV New Drugs Delivered By Email
HCV In The News
Hepatitis C New Drug Research And Liver Health
RSS Feed: Website Updates
Sofosbuvir for Hepatitis C: Simpler, Shorter, Safer?
Prescribing and patient information, FDA articles, videos and important updates
Simeprevir Approved In The United States
OLYSIO™ (simeprevir) Receives FDA Approval for Combination Treatment of Chronic Hepatitis C
Johnson & Johnson's protease inhibitor OLYSIO (Simeprevir) is approved for the treatment of HCV genotype 1, in combination with peginterferon alfa and ribavirin in adults with compensated liver disease, including cirrhosis, who are treatment-naïve or who have failed previous interferon therapy (pegylated or non‑pegylated) with ribavirin.
Simeprevir was approved in Japan this past September , and in Canada on November 20th.
*Updated December 5
HCV Drug Olysio (simeprevir) - The New Kid On The Block
OLYSIO (Simeprevir) Cost? - Janssen has priced Olysio at a wholesale acquisition price of $22,120 per bottle of 28 capsules (150 mg capsules), which is an approximately one-month supply. That's roughly $66,360 for a three-month course.
Lessons Learned - An important lesson we learned from these drugs may serve as a reminder for future DDAs, that is, once telaprevir and boceprevir were used in larger groups of patients, or in "real-life" settings - outside clinical trials, new response rates and adverse effects began to emerge.
Simeprevir drug–drug interactions - Simeprevir has a list of medications that can cause drug–drug interactions Other medications can interfere with the way DDAs are metabolized. The drug–drug interactions can either increase drug concentrations which may cause toxicity and lead to side effects, or decrease drug concentrations leading to a loss of efficacy.
Off Label Use - Simeprevir and Sofosbuvir? - Paul Sax, Editor-in-Chief at NEJM Journal Watch wrote an article this past summer on the possibility of combining simeprevir and sofosbuvir with or without ribavirin, to create an off label interferon-free regimen....
J & J Patient Financial Assistance Program
Important Safety Information
OLYSIO (simeprevir) - Resistant Variant Q80K polymorphism
Olysio-simeprevir/Dosing & Uses, Drug Interactions, Adverse Effects
On November 22nd the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), supported Sovaldi® (sofosbuvir) for the Treatment of Chronic Hepatitis C
The CHMP opinion supports the approval of Sovaldi for the treatment of HCV in combination with other agents. The CHMP's recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union (EU).
FDA Updates - Sofosbuvir
In October the Antiviral Drugs Advisory Committee recommend the approval of Gilead's Sofosbuvir, a nucleotide analog NS5B polymerase inhibitor in combination with just ribavirin for treating adult HCV genotypes 2/3 and in combination with pegylated interferon/ribavirin for genotype 1 and 4 treatment-naive patients.
The FDA does not have to follow the advice of its panels, but most often does. The U.S. health regulators are scheduled to decide whether to approve sofosbuvir by December 8th 2013
For detailed information please download the FDA review package for sofosbuvir and simeprevir.
FDA Updates For Sofosbuvir
FDA Updates For Simeprevir
Quick Links - Hepatitis C Investigational Drugs
News, Research And Clinical Trials
See **Clinical Trials @ HCV Advocate For Enrollment Information
AbbVie is a new, independent biopharmaceutical company composed of Abbott’s former proprietary
News and Research
ABT-450/r - ABT-267 - ABT-333-non- nucleoside
r = ritonavir
**Clinical Trials @ HCV Advocate-AbbVie
News and Research
**Clinical Trials @ HCV Advocate-Achillion
News and Research
Faldaprevir/ (BI 201335)
**Clinical Trials @ HCV Advocate-Boehringer Ingelheim
News and Research
GS-7977 now Sofosbuvir/BMS-790052 now Daclatasvir,
**Clinical Trials @ HCV Advocate-Bristol-Myers Squibb (BMS)
News and Research
GS-0938 and Sofosbuvir
**Clinical Trials @ HCV Advocate-Gilead
News and Research
**Clinical Trials @ HCV Advocate-Idenix
News and Research
**Clinical Trials @ HCV Advocate-Tibotec / Janssen
News and Research
**Clinical Trials @ HCV Advocate-Merck
News and Research
**ClinicalTrials.gov - Danoprevir
News and Research
**ClinicalTrials.gov - Miravirsen
News and Research
**Clinical Trials @ HCV Advocate-Vertex
To learn more about Hepatitis C virus clinical trials or to find out if a study is enrolling patients in your area, please click here.
ClinicalTrials.gov: updated in the last 30 days
- ► 2013 (921)
- Preventive Nutritional Support Helpful During Hepa...
- Hepatitis C - Vertex lowers Incivek view; new drug...
- A Debate on Liver Fibrosis Progression in HIV/HCV-...
- Really? The Claim: Milk Thistle Combats Liver Dise...
- U.S. issues warrant for Canadian linked to illegal...
- The biggest blood supply risk: Tainted platelets-n...
- New targets could enhance the body's defenses agai...
- Hepatitis programs in Egypt improved disease burde...
- Sorafenib improved survival regardless of baseline...
- NEW PERSPECTIVES IN HEPATOCELLULAR CARCINOMA
- Four Michigan Facilities Linked to New Hampshire H...
- UMHS one of six Michigan facilities linked to New ...
- Most Chronic Hepatitis C Patients Report Fatigue
- Liver Cancer Cells Stop Making Glucose As They Bec...
- New genetic target found for diuretic therapy
- Gilead preps late-stage sprint on blockbuster hepa...
- ALS-2200-Vertex Announces Positive Results from Vi...
- Hepatitis C Therapy in Non-genotype 1 Patients: Th...
- World Hepatitis Day 2012
- ALF- New HCV Website and Adds HCV Specialist To He...
- 07/2012 Digital Liver Disease Journal: HCV In Chil...
- HCV Weekly Rewind:Gilead Begins Single Pill Hepati...
- New Hampshire hepatitis C outbreak triggers U.S. f...
- Potentially Curative Treatment in Patients With He...
- Ruling frees FDA to crack down on stem cell clinic...
- Liver transplant may be an option for some patient...
- Patients with HCV may not benefit from HAV vaccina...
- Priority Review for Supplemental New Drug Applicat...
- IDX719-Idenix hepatitis C drug Receives Fast Track...
- BBC to feature Birmingham liver research-Currently...
- Concerns prompt state to change hepatitis C testin...
- Gilead HIV drug as good as Merck's Isentress: stud...
- FDA staff say Roche drug helped diabetics see
- Video-Common questions about Hepatitis C
- WHO-Prevent hepatitis C: Avoid unsafe injections ,...
- NH hepatitis C outbreak: Federal class action laws...
- Idenix: New HCV Treatment Could Be A Game Changer
- Video: Exeter Hospital Expanding Hepatitis C Testi...
- MIT- Analyze Role Of U.S. Airports In The Sread Of...
- Survey: Surgeons Play to Strengths in Early Hepato...
- NIH scientists identify likely predictors of hepat...
- So You Think You’re A Hepatitis C Expert? 35 quest...
- Combination of Tarceva, Nexavar fails to meet main...
- Among new HIV treatment recommendations, all adult...
- Seven States Wrapped Up in Hepatitis C Probe
- Canada-Not Enough Doctors/Nurses Trained To Treat ...
- AIDS Conference Returns to U.S. For First Time Sin...
- HCV Weekend Reading - HIV i-Base and TAG "2012 Pip...
- Hair samples from infants show exposure to anti-HI...
- FDA warns consumers not to eat shellfish from Oyst...
- Testimony in shocking supermodel stem cell fraud c...
- Am I At Risk ? Exposure To Bloodborne Pathogens Du...
- TGIF-HCV Weekly Rewind- Video- US attorney: Former...
- Hepatocellular carcinoma - Brivanib Phase III Does...
- Basic Answers to Complicated Questions for the Cou...
- Traceability Elusive In Global Trade Of Human Part...
- Hepatitis C Patients Speak Out on Infection Contro...
- When a doctor has Hep C
- Watch - The HIV and Viral Hepatitis Epidemic
- Best U.S. Hospitals, 2012-2013
- Treating HCV Improves Insulin Resistance in HIV Co...
- Vitamin E either from supplement or diet may lower...
- Hepatitis C may increase deaths from both liver-re...
- GUT Vitamin B12 supplements may help treat hepatit...
- Video - Milk Thistle No Help in Tough Hepatitis C ...
- Hepatitis C No Longer a Lifelong Illness
- Stem cell research aids understanding of of how ca...
- National patterns and predictors of liver biopsy u...
- Prostate Cancer -Study: Nanoparticles produced fro...
- China - No abnormalities found in Roche Company in...
- Nanozyme shuts down production of hepatitis C viru...
- Escitalopram for the Prevention of Peginterferon-α...
- Assessing Long-Term Treatment Efficacy in Chronic ...
- Patients with cirrhosis at increased risk for pept...
- EU agency lifts lid on drug data secrets
- Statins Safe in Cirrhosis and May Even Have Benefi...
- Supplements Failed to Prevent Cancer
- Clinical Trials Registry Shows Its Strengths, Flaw...
- Multiple Factors Drive Ongoing Rise In Liver Cance...
- PloS ONE- Vitamin D Metabolism in the Response to ...
- A stealthy killer, hepatitis C needs wider screeni...
- IDX184-Idenix Pharmaceuticals Lagging Behind In Br...
- TGIF-Hepatitis C Weekly Rewind: New Webcast On Boc...
- Geno 1-4: Hepatitis C Drug Development Goes from P...
- Can zinc enhance response interferon therapy for p...
- Adherence to Hepatitis C Treatment Interventions: ...
- UW scientists discover why human body cannot fight...
- Protecting the hearts of those waiting for kidney ...
- Sorafenib beneficial in liver cancer regardless of...
- FDA Submission for HepaFat™ Scan and update on Liv...
- Liver Stiffness Predicts Liver Failure, Cancer and...
- Levels of hepatitis C virus higher among African-A...
- Treatment of Patients With HCV Related Cirrhosis: ...
- Boehringer Ingelheim Establishes Translational Res...
- Connecting Enzymes and Diseases - Researcher seeks...
- Drug From Mediterranean Weed Kills Tumor Cells in ...
- H. Pylori in HCV-related Chronic Hepatitis and Cir...
- Alcoholic hepatitis linked to hepatitis C risk
- Houston's Bay Area Gastroenterology Specialists Di...
- Amazing Sunday-Live Liver Donation at Stanford: Si...
- Roche probed for not disclosing 15,000 patient dea...
- US experts demand compensation for injured trial p...
- HCV Weekend Reading- DAA Treatment Webcast: A Guid...
- HCV Weekly Rewind: Hepatitis C-The Silent Dragon
- Stem Cell Lawsuit Against Korean Company
- Hepatitis Clinical Trials - International
- Hepatitis Clinical Trials- US and Canada
- Adding Boceprevir to Hepatitis C Therapy Deemed Pr...
- Hepatitis C - What Is A Biopump ?
- Stem Cell Therapy Shown to be Effective in Treatin...
- New animal model may lead to treatments for common...
- Better treatment, low awareness for hepatitis C
- Idenix: New HCV Drug Could Be A Blockbuster
- Stress Management: How the Unfolded Protein Respon...
- Organ Donation Has Consequences Some Donors Aren't...
- GlaxoSmithKline to pay $3 billion healthcare fraud...
- NH hepatitis C outbreak grows to 27
- Exanthematous Drug Eruptions:Prescription and over...
- IL28B Genotyping in the Management of Chronic HCV
- Scripps Research Institute Scientists Develop Alte...
- ▼ July 2012 (120)
- ► 2011 (1576)
Patient Assistance Program
INCIVEK/Telaprevir and VICTRELIS (Boceprevir) Patient Assistance Programs
Prescribing Information for INCIVEK including the Medication Guide.
VICTRELIS™- Boceprevir: Prescribing Information and Medication Guide
Hepatitis C-New Protease Inhibitor (NS3/4A) Drug Resistance Test
LabCorp has begun offering nationwide its hepatitis C GenoSure NS3/4A assay, which is designed to identify NS3 and NS4A mutations and NS3-associated resistance to a pair of recently approved HCV protease inhibitors.
- 2012 -168 Pages Of HCV FAQs (1)
- a 2013 Conference ID Week (3)
- A 2013 Conference on Retroviruses and Opportunistic Infections (4)
- A Guide 2011-Management Of HCV (2)
- A Guide 2012-Guideline for Nonalcoholic Fatty Liver Disease (1)
- A-2012 EASL-AASLD Special Conference (2)
- A-2012 Update on the Diagnosis and Treatment of Hepatitis C (1)
- A-2012-New guidelines on the management of hepatocellular carcinoma (HCC). (1)
- A-Current status and future directions in the management of chronic hepatitis C (1)
- a-DDW 2011 Meeting (11)
- a-DDW 2012 meeting (21)
- a-DDW 2013 meeting (23)
- A-EASL 2011 Summary (1)
- A-EASL 2012 (79)
- A-EASL 2012 - Guidelines on the Management of Chronic Hepatitis B (1)
- A-EASL 2012 Index (1)
- A-EASL 2012 Internet Symposium (2)
- A-EASL 2012 Summary Of The Meeting (1)
- a-EASL 2013 (51)
- A-EASL 2013 Summary Of The Meeting (1)
- a-EASL 2013-abstract search (1)
- A-List Of Unnecessary Medical Tests (1)
- A-New targets for antiviral therapy (100)
- AASLD 2011 updated hepatitis C practice guidelines (2)
- AASLD 2012-63rd Annual Meeting (73)
- AASLD 2012-STC (1)
- AASLD 2013 (46)
- AASLD 2013 Summary-Symposium (2)
- AASLD Nov 2011 (60)
- AASLD Nov 2011-Pocasts-Videos-Webcasts (2)
- AASLD Nov 2011-Summary (1)
- AASLD Oct2010 (80)
- AASLD Oct2010-summary (1)
- ABT-267 (13)
- ABT-333-non- nucleoside (13)
- ABT-450 (11)
- ABT-450/r (25)
- ABT-450/r and ABT-072 (4)
- ABT-450/r plus ABT-333 (10)
- ABT-450/R/ ABT-267/ABT-333/ribavirin (5)
- Acetaminophen Safety (9)
- ACH-1625 (15)
- ACH-2684 (5)
- ACH-2928 (2)
- ACH-3102 (9)
- acute HCV (4)
- addiction (21)
- Adherence to therapy (13)
- alcohol consumption (17)
- alisporivir (4)
- ALS-2200 (3)
- ALS-2200 (VX-135) (13)
- ALS-2200 and ALS-2158 (3)
- ALS2158 (1)
- ANA598 (5)
- ANA598-setrobuvir (2)
- ANA773 (1)
- ANA958 (1)
- anemia (9)
- antidepressants (5)
- arthritis (5)
- ascites (9)
- Asunaprevir (4)
- autoimmune hepatitis (1)
- Avila Therapeutics™ (1)
- AVL-192 (2)
- bath salts-spice (14)
- Bavituximab (5)
- BCX5191 (2)
- Behind the Headlines (10)
- Behind the Headlines-Vaccine (1)
- Best Hospitals (5)
- BI 201335 and BI 207127 (10)
- BI 207127 (7)
- BILB 1941 (1)
- Bioartificial Liver (3)
- biological "devices" to program cells (1)
- Biopump (1)
- BioScience (2)
- biosimilars (6)
- BIT225 (2)
- BL-8020 (2)
- blood safety (3)
- blood scandal (3)
- bms-650032 (6)
- BMS-650032 (Asunaprevir) BMS-790052 (Daclatasvir) (10)
- BMS-650032 and BMS-790052 (5)
- bms-790052 (18)
- bms-790052-declatasvir (10)
- BMS-986094-INX 189 halted (8)
- BMS-986094-INX 189 on hold (7)
- boceprevir (98)
- Boceprevir FDA Transcript (1)
- boceprevir patient guide (1)
- boceprevir-drug assistance program (3)
- boceprevir-Medication Guide-Prescribing Info (1)
- boceprevir-victrelis (194)
- boceprevir-victrelis-Cost (1)
- boceprevir-victrelis-mericitabine w-SOC (1)
- Bowel (1)
- Brain (7)
- Caleco Pharma (1)
- Canada (3)
- cancer (15)
- cancerous growths gallbladder and/or the bile duct (1)
- CDC (5)
- CDC- World Hepatitis Day 2011 (1)
- CDC- World Hepatitis Day 2012 (4)
- CDC- World Hepatitis Day 2013 (2)
- children treating HCV (15)
- chronic disease (2)
- chronic fatigue (16)
- chronic liver failure (2)
- chronic pain (3)
- cirrhosis (190)
- cirrhosis-complications (13)
- cirrhosis-Vibrio vulnificus-raw oysters (2)
- clinical trials (128)
- clinical trials-Pro-Con (4)
- coffee (31)
- Colloidal silver (2)
- colonoscopy (2)
- compensated cirrhosis (11)
- Complementary and Alternative Medicine (30)
- Counterfeit drugs (8)
- covalent inhibitor (2)
- Creating Functional Hepatic Tissue (1)
- Cryoglobulinemia (5)
- CTS-1027 (5)
- Cyclophilin Inhibitors (1)
- Daclatasvir (9)
- daclatasvir-peg/riba (4)
- Daclatasvir/Asunaprevir (7)
- daclatasvir/asunaprevir/BMS-791325 (5)
- Daily Consensus Interferon (1)
- Danoprevir (17)
- Danoprevir/Mericitabine (3)
- DEB025 (2)
- DEB025- alisporivir (4)
- decompensated cirrhosis (18)
- Dental (4)
- Depression (17)
- diabetes (106)
- diabetes-insulin resistance (8)
- Digestion (2)
- Direct-acting Antivirals (11)
- disease progression (13)
- donation (16)
- drug alerts (1)
- Drug Assistance Programs (5)
- Drug Resistance Test (1)
- drug shortages (1)
- dry eye (3)
- dyspepsia (1)
- EASL (59)
- Economic Burden HCV (2)
- ELAD® Bioartificial Liver (1)
- encephalopathy (28)
- endoscopy (1)
- Epidemic HCV (10)
- Epogen (4)
- ESLD (1)
- faldaprevir (20)
- faldaprevir w-PPI-668/deleobuvir(BI207127) (3)
- faldaprevir/ (BI 201335) (24)
- faldaprevir/BI 207127 (2)
- faldaprevir/DELEOBUVIR (4)
- fatigue (8)
- Fatigue-Cognitive Function-Sleep Quality (3)
- Fatty Liver (126)
- Fatty Liver-RP103 (1)
- FDA (83)
- fibromyalgia (9)
- Fluvastatin (3)
- Foodborne illness (18)
- G7128 (1)
- gallbladder (1)
- gallstones (10)
- gastritis (1)
- Gastroenterologist (2)
- geno1 (104)
- geno2 (57)
- geno3 (65)
- geno4 (32)
- geno5 (6)
- geno6 (11)
- genotype test (1)
- genotypes;All (14)
- green tea (2)
- GS-0938 and Sofosbuvir (1)
- GS-5885 (4)
- GS-7977 now Sofosbuvir (123)
- GS-7977 now Sofosbuvir and simeprevir (TMC435) (8)
- GS-7977 now sofosbuvir / GS-5885 now ledipasvir (20)
- GS-7977 now Sofosbuvir off label use (1)
- GS-7977 now Sofosbuvir Plus Riba (3)
- GS-7977 now Sofosbuvir-FDA Review (10)
- GS-7977 now Sofosbuvir/BMS-790052 now Daclatasvir (11)
- GS-7977 Plus Peg/Riba (3)
- GS-9190 (7)
- GS-9256 (6)
- GS-9451 (2)
- GSK2336805 (4)
- Gut Bacteria (1)
- H pylori (1)
- HALL OF SHAME (44)
- HALT-C (8)
- hav (8)
- hav vaccine (2)
- hbv (113)
- hbv vaccine (4)
- HCV Australia (7)
- hcv abstracts (236)
- HCV agents/drug interactions (1)
- HCV Awareness (84)
- HCV Awareness-screening strategies (36)
- HCV Baby Boomers (41)
- HCV cardiovascular disease (1)
- HCV diet (8)
- HCV Forum (1)
- HCV generics (1)
- HCV hypertension (1)
- HCV natural compounds (1)
- HCV neurocognitive function (1)
- HCV News (1704)
- HCV News-monthly rewind (1)
- HCV News-weekly rewind (20)
- HCV pregnancy (9)
- HCV Protease Inhibitors in Active Drug Users (1)
- HCV replication (3)
- HCV research (97)
- HCV Self-management (1)
- HCV symptoms (3)
- HCV tests (25)
- HCV tests-endoscope (1)
- HCV transmission FAQ (1)
- HCV Vaccine (26)
- HCV vaccine GI-5005 (7)
- HCV Vaccine-TG4040 (MVA-HCV) (2)
- HCV Worldwide (35)
- HCV Worldwide Asia Australia Egypt (2)
- HCV Worldwide-Egypt (1)
- HCV Worldwide-Europe Canada Israel (1)
- HCV Your Health (3)
- HCV-autoimmune diseases (1)
- HCV-Breast Cancer (1)
- HCV-Breast Cancer Risk (1)
- HCV-Editorial (12)
- HCV-Education (76)
- HCV-elderly (5)
- HCV-Insulin resistance (13)
- HCV-Statins (8)
- HCV-TARGET (1)
- HCV/HBV/HIV special populations (1)
- Health Reform (3)
- Health Reform-Insurance (4)
- Healthy you (47)
- hemochromatosis (1)
- HepaFat™ (1)
- Hepatitis-related Renal Disease (1)
- hepatocyte cell transplantation (1)
- hepatologist (2)
- hepatoSys Virtual Liver Network (1)
- herb (36)
- herb-kava (2)
- HEV (4)
- History of HCV (4)
- HIV (120)
- HIV-children (3)
- hiv/hbv-coinfection (1)
- HIV/HCV (80)
- hot topic (9)
- HTAs-host-targeting agents (1)
- human genome (6)
- human interferon alpha lozenges (2)
- Idenix Reports Positive Interim Data for Hepatitis C Drug (1)
- IDX184 (21)
- IDX184-Discontinued (1)
- IDX19368-Discontinued (1)
- IDX19368-hold (2)
- IDX20963/FDA Request More Data (2)
- IDX719 (9)
- if I had.. (9)
- IFNL 4 (1)
- IL-7(CYT 107) (1)
- IL28B (64)
- IL28B Test (2)
- immune system (10)
- IMO-2125 (6)
- Inflammation (3)
- Inflammation Liver (2)
- Inflammatory Bowel Disease (1)
- INFRADURE Biopump (1)
- Inspirational (28)
- Insurance (1)
- Insurance medicare (1)
- interferon (5)
- Interferon Free Combinations (151)
- Interferon lambdas (1)
- Investment News HCV Drugs (22)
- INX 189 (13)
- IP-10 (1)
- ITX-5061 (1)
- IV drug use (1)
- Joint pain (1)
- Just for fun (5)
- JX594/TG6006 (2)
- Lambda (7)
- ledipasvir (GS-5885) (5)
- Lichen Planus (5)
- List Peer-Reviewed Journals (2)
- Liver Abscess (2)
- liver biopsy (14)
- liver biopsy-necessary in all genotypes? (1)
- liver cancer (260)
- Liver cancer CF102 (2)
- Liver Cancer Treatment (77)
- liver cancer treatment-radiofrequency ablation (RFA) (2)
- Liver Cancer-HEAT Study of ThermoDox(R) (3)
- liver cancer-MCT-465 and MCT-485 (1)
- liver cancer/sorafenib (4)
- Liver Cysts (1)
- liver disease (26)
- Liver Fibrosis (114)
- liver function tests (13)
- liver health (82)
- Liver Injury Dietary Supplements (11)
- Liver Injury-Shark liver oil (1)
- Liver Pain (6)
- liver surgery (3)
- liver/anatomy (1)
- Locteron/interferon (3)
- lymphoma (3)
- M11-602 (1)
- marijuana (30)
- marijuana-based prescription drug (1)
- MBX-700 and MBX-701 (formerly SCH 900942 and SCH 900188) (1)
- Mediterranean diet (2)
- Men and HCV (4)
- microspheres (3)
- Milk thistle (24)
- Miracle Mineral Solution-MMS (1)
- Miravirsen (9)
- miRNAs (1)
- MK-5172 (15)
- MK-5172/peg/riba (1)
- MK-5172/Vaniprevir(MK-7009) (1)
- MK-7009 (4)
- MK-8742 (4)
- monoclonal antibody GS-6624 (1)
- Morbidity-SVR (7)
- Mortality (16)
- nanoparticles (3)
- Nanotechnology (3)
- Natural leukocyte interferon alpha (Alfaferone) (1)
- Neutropenia HCV Treatment (5)
- new drugs (5)
- new hcv drugs (55)
- newly diagnosed (10)
- newsletters (53)
- Nitazoxanide (2)
- noni juice (1)
- noninvasive tests for fibrosis (42)
- nonresponders (9)
- NS5A inhibitor (2)
- NSAID (7)
- nucleoside inhibitors (1)
- null responders (10)
- occult hepatitis C virus infection (1)
- Off Topic (34)
- online pharmacy (1)
- Oral interferon (1)
- organ harvesting (11)
- organ trafficking (5)
- organ trafficking- U.S (1)
- organ-imported tainted tissue (1)
- Origin Of Hepatitis (2)
- Other Conditions Related To HCV (51)
- Other Conditions Related To HCV-Vasculitis (5)
- Other Health News (121)
- OTHER INFECTIOUS DISEASE (20)
- outsourcing clinical trials (3)
- outsourcing drugs (7)
- partial responders (3)
- Pediatric liver disease (3)
- Pegasys (10)
- Peginterferon (77)
- PegIntron (4)
- Peripheral Neuropathy (2)
- PF-05095808 (1)
- Pharmaceuticals (146)
- Pink eye-Sty-and other eye conditions (1)
- platelets (4)
- polymerase inhibitor (16)
- Porphyria Cutanea Tarda (PCT) (2)
- Post Treatment Symptoms (1)
- PPI-383 (1)
- PPI-461 (3)
- PPI-668 (3)
- primary biliary cirrhosis (PBS) (1)
- probiotics (2)
- procrit (4)
- prognostic test:response to therapy (1)
- promacta (1)
- prostate cancer (1)
- protease inhibitor (33)
- protease inhibitor- (NS3/4A) Drug Resistance Test (2)
- PSI-7977 (24)
- PSI-7977 and PSI-938 (1)
- PSI-7977-TMC435 (3)
- PSI-7977/ Daclatasvir-(BMS-790052) (1)
- PSI-938 (6)
- PSI-938-Halted (1)
- Pulmonary fibrosis (1)
- Q80K polymorphism (1)
- Quackery (10)
- Questions About HCV (4)
- rash (10)
- recall (25)
- regeneration (6)
- regenerative Medicine (17)
- relapse (8)
- resistance to protease inhibitors (17)
- response-guided therapy (4)
- RG7128 (9)
- ribavirin (27)
- Ritonavir (1)
- rituximab (2)
- salt (5)
- SB 9200 (1)
- scientists grow human livers in laboratory (7)
- SCY-635 (5)
- SCY-641 (1)
- Seasonal Flu Vaccine (10)
- selenium (2)
- setrobuvir (1)
- side effects (71)
- side effects-direct-acting antivirals (19)
- side effects-eyes (8)
- side effects-telaprevir (4)
- silibinin (4)
- silymarin (4)
- Simeprevir (42)
- Simeprevir now Olysio (11)
- Simeprevir now Olysio FDA Approved (5)
- Simeprevir off label use (1)
- Simeprevir/Samatasvir (IDX719) (1)
- Simeprevir/TMC647055/ Samatasvir (IDX719 (1)
- SIR-Spheres microspheres (3)
- Small fiber neuropathy (2)
- sofosbuvir and ABT-450 (1)
- Sorafenib (6)
- sovaprevir (6)
- Sovaprevir (Formerly ACH-1625) (7)
- Sovaprevir/ACH-3102 (2)
- sphincter of Oddi (3)
- spleen (6)
- SPONTANEOUS CLEARANCE (13)
- Standardization of Terminology of Virological Response (1)
- Starting HCV Treatment (75)
- STAT-C (3)
- stem cell lawsuit (2)
- stem cell tourism (7)
- stem cell-diabetes (1)
- stem cells (82)
- stem cells-pluripotent (2)
- stem-cell-derived liver tissue model (1)
- stigma (1)
- supplements (22)
- support (48)
- support-hotline (5)
- Surgery in liver disease (3)
- svr (81)
- svr durability (4)
- svr-pitavastatin (Livalo) (1)
- svr-rapid response (1)
- SVR24-SVR12-SVR4 (9)
- Tattoos (2)
- telaprevir (125)
- Telaprevir FDA Transcript (1)
- telaprevir medication guide (1)
- telaprevir patient assistance (3)
- telaprevir prescribing information (1)
- telaprevir with VX-222 (20)
- telaprevir-incivek (235)
- telaprevir-incivek-Cost (3)
- Tenofovir (2)
- Terry's nails (1)
- TG4040 (2)
- Thalidomide (1)
- The natural history of hepatitis C (3)
- TheraSphere (2)
- Thrombocytopenia (4)
- Thrombocytopenia-Promacta (1)
- thrombosis (3)
- thyroid (11)
- Timeline Hepatiits (1)
- Timeline Hepatitis (1)
- TMC435 (26)
- TMC435 (Simeprevir) (36)
- TMC435-BMS-790052 (3)
- TMC647055 (3)
- TMC647055 and IDX719 (1)
- TMC649128 (4)
- toxicity (28)
- transmission (72)
- Transmission clinical setting (93)
- Transmission clinical setting-Government Report 2012 (1)
- Transmission of HCV Through Transplanted Organs (2)
- transmission-needlestick (3)
- transplant (182)
- transplant tourism (7)
- Transplant- Telaprevir/Boceprevir (3)
- transplant-certican (1)
- Transplant-GS-7977 now Sofosbuvir (1)
- transplant-MELD (8)
- Triad Prep Pads (16)
- TT-034 (1)
- tylenol (17)
- upper abdominal pain (2)
- varices (14)
- video (269)
- viral load (11)
- Virtual Liver (1)
- virus research (3)
- vitamin A (6)
- vitamin B12 (3)
- vitamin D (40)
- vitamin E (7)
- Vitamin E-TE/TCP supplements (1)
- vitamin k (1)
- vitamins (11)
- weekend reading (53)
- wellness (52)
- women (13)
- Xifaxan (1)
- XIX International AIDS Conference (4)
- zalbin (1)
- zinc (2)
Click here to order a FREE Home Access Hepatitis C Test Kit
How Soon Should I Get Tested After Exposure ?
After the exposure (especially if the blood exposure involved another person known to have the hepatitis C virus), it is recommended that testing for the hepatitis C antibody be performed at 4 to 6 months after the exposure OR that testing for the hepatitis C virus itself (a test often called an HCV PCR or hepatitis C viral load test) be performed 4 to 6 weeks after the potential exposure. These tests are done to determine whether or not hepatitis C infection has occurred as a result of the exposure.;
FAIR USE NOTICE:
If this site contains copyrighted material the use of which has not been specifically authorized by the copyright owner, it is being made available in an effort to advance the understanding of the ethics dealing with medical practice, medical care, new drug research, drug trials, science and scientific research, human rights, social justice and, in addition, the law and politics which cover these areas. It is believed that this use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed to visitors of this “HCV New Drugs Blog” without profit to the blog or to those who by visiting this blog have expressed interest in receiving the included information for research and educational purposes. The material in this site is provided for educational and informational purposes only, and is not intended to be a substitute for a health care provider's consultation. Please consult your own appropriate health care provider about the applicability of any opinions or recommendations with respect to your own symptoms or medical conditions. The information on this site does not constitute legal or technical advice
- New HCV Drugs
- Keeping current on the potential arrival of new improved hepatitis C drugs. As once a hepatitis C patient myself (I successfully treated the virus with standard HCV therapy in 2000) I understand the difficult decisions and overwhelming fear that ensues after being diagnosed with this serious and life-changing disease. This blog serves as a starting point for information on the rapidly evolving number of new agents in development to treat hepatitis C. Tina